OREANDA-NEWS. June 02, 2016. Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that CEO Graham Lumsden has been invited to present at BIO 2016 which is being held at the Moscone Center, 747 Howard Street, San Francisco from June 6-9 2016.

The presentation will provide information on the progress of its clinical lead antibiotic, iclaprim, into pivotal phase III trials and will be held in presentation room 1 on Monday June 6 commencing at 2.45pm.

The BIO convention brings together over 15,000 biotechnology and pharma leaders, covering a wide spectrum of life sciences areas including drug discovery, bio-manufacturing, genomics and more.